Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that adolescents with alopecia areata receiving ritlecitinib 50 mg daily showed notable hair regrowth over three years, as seen in both clinician- and patient-reported outcomes. However, the decreased number of participants at later stages limits the findings.

In this study, researchers found that among patients with severe alopecia areata, a change in SALT scores of 42 or 43 points represents meaningful improvement, highlighting the need to consider individual treatment goals beyond conventional low SALT score targets when assessing treatment benefits.

In this phase 2b/3 trial, ritlecitinib showed effectiveness in treating alopecia areata patients with varying hair loss profiles, significantly improving patient-reported outcomes for hair regrowth and satisfaction compared to placebo, regardless of the hair loss type and extent at baseline.

This study suggests that the action of minoxidil in stimulating hair growth likely occurs at the follicular dermal papilla, though it does not induce new follicle formation.

This study analyzed social media posts on alopecia areata treatments and found that while most reported perceived improvement, many treatments, particularly dexamethasone, were associated with underlying negative emotions.

This study analyzed social media posts and found discrepancies between patient-reported satisfaction and emotional responses to alopecia areata treatments, highlighting potential gaps between perceived and clinical efficacy.

In this note, editors discuss the reproduction of medical content by Dr. Paul E. Marik, related to standardized coronavirus treatments, emphasizing that the materials appear effective and cautioning readers to consult their doctors for guidance.

In this phase 2a study of adults with alopecia areata, researchers observed that ritlecitinib treatment did not result in significant differences in brainstem auditory evoked potential changes or axonal swelling compared to placebo, suggesting the dog toxicity findings may not be clinically relevant in humans.

This study found that Ritlecitinib significantly reduced hair loss in patients with alopecia areata by lowering SALT scores at weeks 12 and 24 compared to placebo, with acceptable safety but increased minor side effects like headaches and acne.

This case report highlights a rare presentation of hair-thread tourniquet syndrome in a two-year-old child, emphasizing that prompt identification and removal of the constricting fiber is crucial for successful treatment and prevention of tissue damage.

In this study, 82% of systemic lupus erythematosus patients at a tertiary care center in India exhibited skin manifestations, including photosensitivity, malar rash, discoid rash, and oral ulcers.

In this study, ritlecitinib 50 mg produced clinically meaningful improvements in scalp hair regrowth over three years for patients aged 12 and older with severe alopecia areata, with 65.1% showing substantial hair regrowth and 31.2% achieving complete regrowth, while also maintaining a consistent safety profile.

This review discusses the pharmacology and toxicology of cyclooxygenase in skin, highlighting its role in inflammation, wound healing, and tumorigenesis, without presenting new clinical results.

In human follicular cells, this study found that an Annurca apple-based dietary supplement may stimulate the production of hair keratins, suggesting potential benefits for hair growth.

This study identified aging-related epigenetic and transcriptomic biomarkers and suggested that curcumin might target and inhibit the JUN gene, implicating potential therapeutic strategies against aging.

This study found that human placental extract significantly improved melasma, chronic ulcers, and alopecia areata without major adverse effects, suggesting its effectiveness and safety for these conditions.

This study evaluates the efficacy and safety of a higher dose (100-mg) of ritlecitinib for treating severe alopecia areata, comparing it to external and synthetic placebo control groups.

This study suggests that combining LMWHA solution and HCO might improve mild to moderate urinary incontinence in women with GSM, potentially offering benefits over HA therapy alone, but further research is needed.

This review discusses the developments over the past five years in nanozyme-based theranostics for tumor therapy, including their classification, design, and synergistic strategies. It also outlines the challenges and prospects of using nanozymes to enhance selectivity, biosafety, repeatability, and stability in therapeutic applications.

This study found that ritlecitinib improved patient-reported outcomes related to hair growth in individuals with alopecia areata, with some experiencing clinically meaningful hair regrowth, although changes in emotional symptoms and activity limitations were minimal and similar across treatment groups.

This source reports that based on international Phase 3 trial results, the JAK1/2 inhibitor baricitinib was approved in Japan in June 2022 for treating extensive alopecia areata, offering a potentially useful treatment option.

In this study, testing Annurca apple extract on human follicle dermal papilla cells indicated its potential to prevent patterned hair loss by reducing oxidative stress and increasing factors involved in hair growth.

In this triple-blind, randomized clinical trial, researchers found that oral Amla syrup significantly increased the anagen-to-telogen hair ratio and satisfaction levels in women with Female Androgenetic Alopecia compared to placebo, suggesting its potential benefit for treating androgenic hair loss.

In this study on mouse preputial glands, suppressing ATG7-dependent autophagy delayed age-related changes, affected lipid metabolism, and reduced pheromone production, highlighting autophagy's roles in glandular homeostasis and cell breakdown.

This case study reports that a 9-year-old Nepalese boy with tinea capitis successfully recovered with systemic antifungal therapy, though experienced focal alopecia without recurrence at a two-year follow-up.

This study found that testosterone modulates vascular cell behavior through direct actions that do not rely on its conversion to estradiol.

This study reports that polyphenols from Annurca apples may safely promote hair growth and protect against chemotherapy-induced alopecia without interfering with chemotherapy regimens.

This review examines the differences in dermatology practices between Europe and North America, noting that European dermatologists often prioritize evaluating patients' psychosocial factors and utilize nondrug treatments, unlike their North American counterparts.

This study suggests that fish oil, specifically its components EPA and DHA, play a beneficial role in promoting skin health by supporting epidermal growth and reducing proinflammatory cytokines.

This study found that a topical henna formulation may improve symptoms like itching, burning, and redness in patients with recessive dystrophic epidermolysis bullosa, but larger controlled studies are needed.